GRACE news

Latest 2 stories · newest Jun 18, 2026

GRACE

Grace Therapeutics presents corporate strategy for GTx-104 and GTx-102 programs

Grace Therapeutics released a June 2026 corporate presentation outlining its drug development pipeline and regulatory strategy. The company is pursuing FDA approval for GTx-104 for aneurysmal subarachnoid hemorrhage treatment and advancing GTx-102 for Ataxia Telangiectasia, with near-term regulatory…

Regulatory Jun 18, 2026 sentiment +0.50 SEC filing ↗

GRACE

Grace Therapeutics enters consulting agreement with Carrie D'Andrea effective June 5, 2026

Grace Therapeutics, Inc. executed a consulting agreement with Carrie D'Andrea for professional services with compensation and terms detailed in Exhibit A. The agreement includes standard confidentiality obligations with a 10-year post-termination non-disclosure period.

Other Jun 5, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same GRACE feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/GRACE/newsSTART FREE